Biogen Inc. diskutieren
Biogen Inc.
WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /
157,10 €
-0,95 %
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Stifel Nicolaus from $202.00 to $214.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at TD Cowen.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Royal Bank Of Canada from $217.00 to $233.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in First Hawaiian Inc diskutieren